Navigation Links
Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
Date:10/27/2008

POT-4 is the first complement inhibitor to be tested in AMD patients

LOUISVILLE, Ky., Oct. 27 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that the Company will be presenting its ASaP Phase I clinical data for its leading drug candidate, POT-4, during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, GA, on November 7, 2008.

Cedric Francois, President and CEO of Potentia Pharmaceuticals, said, "POT-4 is the first of several complement inhibitors that will ultimately be tested in macular degeneration. The role of complement in this disease was established in 2005 as the first breakthrough discovery resulting directly from the human genome project. If complement inhibition is successful at treating macular degeneration, it would be the first of hopefully many new drugs born out of the human genome project, and usher in an era of improved healthcare for millions of patients."

Dr. Philip J. Rosenfeld, M.D., Ph.D., Professor of Ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine in Miami, FL, and a clinical investigator in the study, will present the data on Potentia's behalf.

POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF) in the eye. Based on this mechanism of action, POT-4 holds the potential to be effective against both dry and wet AMD. POT-4 has shown early positive safety results in its Phase I study.

For more information on the presentation at AAO:

Title: Complement C3 Inhibitor POT-4 for AMD

When: Friday, November 7 at 9:01 AM EST

Location: Hall A-3 Session Room

Session: Retina 2008: Vistas and Viewpoints

Section II: AMD, Part II

About AMD

AMD is the leading cause of blindness in the elderly of the western world and affects more than 10 million patients in the United States alone. The current standard of care for AMD relies primarily on angiogenesis inhibitors, an approach geared towards the approximately 10-15% of AMD patients with complications resulting from ocular angiogenesis (growth of new blood vessels and bleeding in the back of the eye). No drug currently on the market has been approved for the treatment of the remaining patients, who suffer from the so-called "dry" form of the disease.

About the Complement System and POT-4

Complement activation is an inflammatory process involving dozens of plasma proteins, ultimately leading to cell membrane disruption through the membrane attack complex (MAC). Activation of the complement system is an important part of the body's defensive immune response against pathogens such as bacteria and viruses. In spite of its defensive function, inappropriate or excessive complement activation can have destructive consequences if left unchecked. Over the past three years, multiple scientific publications have strongly linked variants of genes encoding components of the complement system with a predisposition toward AMD.

POT-4 binds tightly to complement component C3, preventing its participation in the complement activation cascade. As C3 is the central component of all major complement activation pathways, its inhibition effectively shuts down downstream complement activation that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factors (VEGF).

About Potentia

Potentia Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the eye such as age-related macular degeneration.

Media Requests:

Paul Kidwell

(617) 296-3854

paulkidwell@comcast.net

Contact for Potentia Pharmaceuticals:

Pascal Deschatelets

(502) 569-1053


'/>"/>
SOURCE Potentia Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
9. Discovery of creator gene for cerebral cortex points to potential stem cell treatments
10. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
11. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2020)... ... February 25, 2020 , ... Continuing ... recently published the results of its safety assessment on the biotechnologically produced 3-Fucolsyllactose ... in human milk. These complex carbohydrates are indigestible and therefore function as a ...
(Date:2/21/2020)... ... February 20, 2020 , ... ... complex, efficient and elegant chemistry. Humans have been increasingly successful in innovating ... , Through rapidly evolving technologies and strategies for modern molecular biology (e.g., ...
(Date:2/21/2020)... ... ... Join Forrest Brown, Engineering Services Manager – Northeast Region and Jarred Christofaro, Engineering ... session on Wednesday, February 26, 2020 at 1pm EST to learn about:, ... add manufacturing flexibility in the future, especially for CMOs , C&Q Strategy ...
(Date:2/19/2020)... ... February 18, 2020 , ... ... characterizing microbiome populations down to the strain level, recently unveiled a novel DNA ... for efficient and unbiased isolation of high molecular weight (HMW) single-stranded DNA (ssDNA) ...
Breaking Biology Technology:
(Date:3/5/2020)... ... March 05, 2020 , ... ... technology . The AlphaSTEM Test™ is the first, and still only, available ... Other technologies that attempt to provide information about the number and quality of ...
(Date:3/4/2020)... BOSTON (PRWEB) , ... March 04, 2020 , ... ... startup founders and CEOs to apply to the MedTech IGNITE program’s 2020 IGNITE ... mentorship and networking curriculum to attract and nurture the next generation of medtech ...
(Date:3/4/2020)... Md. (PRWEB) , ... March 04, 2020 , ... ... cell (hMSC) working cell banks and hMSC bioprocess systems, announces today a significant ... using its innovative cellular starting materials. The patient has been treated by RoosterBio’s ...
Breaking Biology News(10 mins):